Mammalian target of rapamycin (mTOR) inhibitors (such as sirolimus), while reducing fatty acid synthesis via inhibition of fatty acid synthase, may interfere with insulin signaling pathways, increasing the risk of post-transplant insulin resistance and hyperglycemia, thereby indirectly affecting lipid metabolism. Here, MTOR is linked to Hyperglycemia.